Analysis of the same dataset revealed that bone-metastatic CRPC tumor samples exhibited higher expression levels of two key steroidogenic enzymes, AKRIC3 and CYP11A1, than that in primary prostate cancer (Figures S1D-E). This evidence concerns the gene CYP11A1 and prostate cancer.